跳至主要内容
临床试验/NCT02213718
NCT02213718Unknown4 期

The Effect of Desflurane on Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting

Huazhong University of Science and Technology1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2014年7月最近更新:
适应症
干预措施

试验速览

阶段
4 期
入组人数
60
试验地点
1
主要终点
Serum Concentration of cTnI

研究概览

简要总结

This study is to assess the effect of desflurane on myocardial function in patents who underwent coronary artery bypass grafting.

详细描述

Desflurane, one of the third-generation inhaled anesthetics, is introduced in clinical practice in 1990s. Decades of clinical use has provided evidence for desflurane's safe and efficacious use as a general anesthetic. Compared with other volatile anesthestics, it has several characteristics: lower blood and lipid solubility, more stable in vitro and the lowest in vivo metabolism. Its particular low fat solubility properties promote rapid equilibration and rapid elimination at the end of anesthesia which reduces slow compartment accumulation and promotes predictable emergence, early extubation, and the ability to rapidly transfer patients from the operating room to the recovery unit. In addition, several investigations found that patients with desflurane anesthesia recovered their protective airway reflexes and awakened to a degree sufficient to minimize the stay in the high dependency recovery area.

A burgeoning body of investigations has shown that desflurane can directly act on myocardial and vascular functions. Desflurane has coronary vasodilative effects in in situ canine hearts which is comparable to sevoflurane does. Although it is controversial regarding to the effect of desflurane on myocardial excitation-contraction coupling and electrophysiologic behavior, a elaborated study found desflurane induced a positive inotropic effect in rat myocardium in vitro compared with isoflurane. A recent study suggested that desflurane decreased right ventricular contractility much less and maintained the right over left pressures ratio at more favorable values compared with sevoflurane. Furthermore, substantial investigations found that clinically relevant concentration desflurane preconditioning or postconditioning could protect myocardium from ischemia-reperfusion in mammalian animal models or isolated human cardiac tissues. However, it is unclear whether desflurane can provide protection for patients with coronary artery disease. Therefore, this study is designed to investigate the effect of desflurane on myocardial function in patents who underwent coronary artery bypass grafting.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
40 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with CAD

排除标准

  • Left ventricular ejection fraction <40%
  • Left ventricular aneurysm
  • Acute myocardial infarction in latest two weeks, atrial fibrillation
  • Associated vascular diseases, severe systemic diseases involving the renal and hepatic systems
  • Respiratory disease( forced vital capacity less than 50% of predicted values )
  • Preoperative left bundle branch block -

研究组 & 干预措施

Desflurane

Experimental

desflurane (7%-8% end-tidal concentration), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h)

干预措施: Desflurane (Drug)

Desflurane

Experimental

desflurane (7%-8% end-tidal concentration), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h)

干预措施: sufentanil (Drug)

propofol

Active Comparator

intravenous administration of sufentanil (1μg/kg), etomidate(0.3mg/kg) and vecuronium (0.08mg/kg). The anesthesia is maintained with propofol (TCI:3.5-4.0μg/min), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h).

干预措施: propofol (Drug)

propofol

Active Comparator

intravenous administration of sufentanil (1μg/kg), etomidate(0.3mg/kg) and vecuronium (0.08mg/kg). The anesthesia is maintained with propofol (TCI:3.5-4.0μg/min), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h).

干预措施: sufentanil (Drug)

结局指标

主要结局

Serum Concentration of cTnI

时间窗: 48 hours

at the begingineg of the surgery,immediately after surgery,4 hours after the surgery, 8 hours after the surgery, 12 hours after the surgery, 24 hours after the surgery

次要结局

  • Continuous Monitoring of ECG(participants will be followed for the duration of hospital stay, an expected average of 5 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Xin Chen

staff

Huazhong University of Science and Technology

研究点 (1)

Loading locations...

相似试验